AstraZeneca: to present advances in oncology

(CercleFinance.com) - AstraZeneca will present new data on its cancer drug pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from 2 to 6 June 2023.


More than 130 abstracts will present 22 approved and potential new drugs in the company's diverse oncology portfolio and pipeline, including 11 oral presentations and a late-breaking plenary presentation of overall survival (OS) results from a Phase III trial of Tagrisso (osimertinib) in certain lung cancers.

With our leading portfolio of medicines in lung cancer, we aim to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will be presenting important milestones towards this goal with ADAURA's overall survival data reinforcing Tagrisso as the backbone therapy in EGFR-mutated lung cancer, it announced.


Copyright (c) 2023 CercleFinance.com. All rights reserved.